Khephren Thuram, the Unexpected Surgery and Juventus's Financial Puzzle

Juventus announced unwelcome news on a quiet Thursday: Khephren Thuram had to undergo arthroscopic surgery on his right knee to treat patellar chondropathy. They say women don't understand the number 10. But I saw the number 10 cry. And I understand that a surgery announced on Thursday, just three days before facing AC Milan, is never a routine decision. In fact, Thuram has not played a single minute in the 2026-26 season. A 25-year-old player, signed from OGC Nice for around €20-25 million in July 2026, is at the peak of his career but has disappeared from the squad. The contract runs until 2029, but that transfer fee is being amortized while the player cannot contribute on the pitch. This is not a financial crisis, but it is a short-term asset impairment that Juventus must absorb. The context of this weekend's match makes the issue even clearer. Juan Cabal, the left-back, also suffered a low-grade tear in his left thigh. Two injuries announced on the same day, before a match against direct rival AC Milan, creates a media narrative tinged with crisis. But looking closely, the problem is not in the tactical system. Thiago Motta still has Locatelli, Koopmeiners, Douglas Luiz, and McKennie in midfield. The numbers are sufficient, but the specific profile of a ball-carrying, physical duel-winning, vertical-progression midfielder like Thuram has no direct replacement. The slow buyer buys joy, the fast buyer buys the future. And Juventus is paying for a future that never arrived. What's notable is the decision to operate now, rather than continue conservative management, which shows the medical staff judged that Thuram's cartilage condition would not heal on its own. The surgery was performed by Dr. Bertrand Sonnery-Cottet in Lyon, with the club's medical director Luca Stefanini present. The choice of a renowned French knee specialist for a French player may reflect personal trust, but it could also indicate that the cartilage damage was more extensive than a routine arthroscopic cleanup. The typical recovery timeline for chondroplasty is 4 to 8 weeks, meaning Thuram is unlikely to return before late October or November 2026. Moscow that night was not as cold as the gaze that avoided me. Now, I see that same coldness in how Juventus handled this information. Financially, this injury does not trigger FFP violations, but it raises questions about transfer strategy. If Juventus seeks reinforcement in the January 2026 window to cover Thuram's absence, they face the risk of overpaying. The January market always inflates prices, and the pressure of a title race could push sporting director Cristiano Giuntoli to break the spending discipline he has built. A signature is just the last recognized lie. But before signing a new contract, Juventus must ask itself: are they repeating the mistake of spending on a player with an injury history? Cabal, with a low-grade thigh tear, typically needs 2-4 weeks to recover. The coincidence of two simultaneous injuries raises questions about the squad's fitness management. If Juventus performs well against AC Milan despite the absences, the crisis narrative will dissipate. If they struggle, the injuries become a convenient excuse and a source of continued pressure on the manager and medical staff. The transfer office is full of cigarette smoke and patriarchy. I sat still, they defeated themselves. And Juventus is defeating itself in the media battle before the most important match of the early season. Deeper still, Thuram's injury reveals a systemic issue. Patellar chondropathy is a chronic condition that can recur. If not managed well, the player's market value, estimated at €25-30 million on Transfermarkt, could decline significantly. Juventus, as a destination club, depends on the narrative of developing and maximizing player value. A high-profile signing struggling with a chronic injury erodes fan confidence and the trust of potential partners. The real story here is not a knee surgery. It is the question of leadership patience, the ability to assess medical risk in recruitment strategy, and whether Juventus has the courage not to panic-buy in January. The quietest summer is where the loudest contracts are born. But sometimes, the most frightening silence comes from the medical room, where life-or-death decisions are made without stadium lights. The match against AC Milan on Sunday will be the first test. But the real test will come in January, when Juventus must decide: reinforce or trust the current squad. And when Thuram returns, he will face not only opponents on the pitch but also the skeptical gaze of those who have already labeled him a 'flop'. What do women know about the number 10? I know that a 25-year-old player with a contract until 2029 cannot be written off after one surgery. But I also know that football never waits for anyone. And Juventus, with its history and ambition, will have to find its own answer.